Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Myeloid 1

Conditions

Multiple Myeloma 7Pain, Postoperative 5Pain 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Burkitt Lymphoma 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Leukemia, Hairy Cell 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Carcinoma in Situ 2Breast Neoplasms 2Agnosia 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Papillomavirus Infections 1Ovarian Neoplasms 1

Interventions

Cyclophosphamide 52Vincristine 32blinatumomab 30Prednisone 27Methotrexate 27Cytarabine 25Dexamethasone 23Specimen Handling 21Rituximab 20Doxorubicin 19merphos 18Mercaptopurine 18Etoposide 18fludarabine 17Biopsy 17prednylidene 16deltacortene 16N,N-dicyclohexyl-isoborneol-10-sulfonamide 16Calcium Dobesilate 16dexamethasone acetate 15dexamethasone 21-phosphate 15auricularum 15Inotuzumab Ozogamicin 15pegaspargase 14azathiopurine 14venetoclax 13Asparaginase 13Spinal Puncture 12Leucovorin 12CT-P10 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Acetaminophen × 1 year × Clear all
NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
340 enrolled
Lymphoid

Burkitt Lymphoma

NCT03913559 2026-02-12

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

St. Jude Children's Research Hospital

Phase 2 Terminated
5 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡